AzTrials
AzTrials

End-Stage Kidney DiseaseNCT06377293

Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients

A study testing Dialysis-specific therapeutic diet in people with End-Stage Kidney Disease, run by Far Eastern Memorial Hospital at 1 site in Taiwan.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

In patients with kidney failure, disturbances in bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites are frequent. Read more about this study

Who is it for?
Ages 20 years and older
Conditions the study is for
End-Stage Kidney Disease
What is being tested?
Dialysis-specific therapeutic diet
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteTaiwan
Study dates
1 May 2025to Jun 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects with aged older than 20 years
  • End-stage kidney disease (ESKD) undergoing maintenance dialysis for more than three months
  • Must have adequate dialysis
  • Good dietary compliance

Who cannot join

  • Serum albumin level less than 2.5 g/dL
  • Hospitalization within the past 4 weeks
  • Prebiotics, probiotics, symbiotics or antibiotics use within the past 4 weeks
  • History of psychiatric disorders
  • Having mental retardation
  • Those who dislike of the study meals
  • Soft diet requirement
  • Vegetarian

Trial locations and contacts

1 site in 1 country.

Taiwan1 site
  • Far Eastern Memorial Hospital

    New Taipei City, Banciao Dist., 220

Other trials in Taiwan

About this study

Official title: Effects of Dialysis-specific Therapeutic Diet in Dialysis Patients

In patients with kidney failure, disturbances in bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites are frequent. Unhealthy diet causes altered mineral metabolism, elevated uremic toxin level, immune dysregulation, metabolic abnormalities, inflammation, protein-energy wasting and dysbiosis. The investigators hypothesize that therapeutic diet intervention reverses these uremic complications and thereby reduces cardiovascular risk in patients with kidney failure. In this study, the investigators crafted 4-week dialysis-specific therapeutic diet to illustrate the clinical implications of therapeutic diet for dialysis patients.

Read the detailed description

In patients with kidney failure, disturbance in bone turnover and mineral metabolism, and nutritional deficiency is prevalent, leading to vascular calcification, uremia, inflammation, immune dysregulation, metabolic alteration, and gut microbial dysbiosis, and these abnormalities are associated with increased risk of fracture, extraskeletal or vascular calcification and cardiovascular mortality. It is well known that an unhealthy diet plays an important role in bone-mineral metabolism, uremia, inflammation, metabolomics, protein-energy wasting, and dysbiosis, and therefore nutritional therapy may help to manage these uremic complications to reduce cardiovascular risk in patients with kidney failure. Importantly, serum biomarkers regarding the above-mentioned abnormalities are acutely and closely related to food intake. To our knowledge, no study to date has examined the multifactorial effects of nutritional intervention on bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients.

To examine the beneficial effects of nutritional intervention on clinical outcomes, the investigators crafted the dialysis-specific therapeutic diet which was characterized by adequate calorie and protein amounts, natural food ingredients with a low phosphorus-to-protein ratio, higher portions of plant-based food, and high fiber content. In the previous studies, the investigators found that the therapeutic diet rapidly reversed mineral abnormalities within the 1-week intervention period. Among these changes, reduction in serum phosphate level achieved in 2 days, modifications of intact parathyroid hormone (PTH) and calcium levels in 5 days, and reductions in intact and C-terminal fibroblast growth factor-23 (FGF23) levels in 7 days of therapeutic diet intervention. Although the therapeutic diet tended to change uremic toxin level, neither inflammatory nor nutritional markers changed which may be explained by short duration of intervention. It is of interest to know whether the therapeutic diet has a favorable effect on bone turnover, vascular calcification, and gut microbial dysbiosis. In this continuity planning, the investigators are therefore going to analyze the 4-week diet-induced changes in biomarkers regarding bone turnover, metabolites, vascular calcification, and gut microbial metabolites in addition to the previously assessed mineral metabolism, uremia, inflammation, immunity, and nutrition in dialysis patients.

This project aims to explore the multiple diverse effects of dialysis-specific healthy diet on the changes of bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients. In contrast to the previous approaches, bone biomarkers for both of bone formation and bone resorption, vascular calcification biomarkers, and gut microbial metabolites will be comprehensively examined. Revealing a complex correlation between the nutritional factors and bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial dysbiosis, this project may shed light on understanding of diet-mediated bone-mineral and uremic homeostasis and uncover strategies of nutritional therapy. A better knowledge of diet-induced pathway on human body homeostasis may lead to new strategies for preventing fracture, vascular calcification or cardiovascular disease risk.

It is to conduct a randomized controlled trial with cross-over design at a dialysis unit of tertiary teaching hospital in Northern Taiwan. Subjects with aged older than 20 years, end-stage kidney disease (ESKD) undergoing maintenance dialysis for more than three months, having adequate dialysis and good dietary compliance will be included. Each participant will receive one study meal during the run-in period to give him or her the opportunity to assess whether he or she can successfully complete the study meals over the next 4 weeks, thus excluding participants who do not prefer the dietary intervention. Then, participants will be randomly assigned into two groups: group A and group B. Those in group A will receive study diet for 4 weeks, followed by 16-week washout period and then receive 4-week usual diet. The opposite order of diets will be prescribed in group B. The study meals are prepared in the hospital cafeteria. Dietary compositions of the study diets were analyzed before the start of the study. The study outcome measures are difference in change-from-baseline values of abnormal mineral metabolism, altered bone turnover, vascular calcification, uremic toxin production, immune dysregulation, metabolite alteration, nutrition, inflammation and gut microbial metabolites between the therapeutic diet and the usual diet.

Being tested
Dialysis-specific therapeutic diet
Medical subject headings
Kidney Failure, Chronic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dialysis-specific therapeutic dietOther

    A healthy diet for dialysis patients

Study groups in NCT06377293
Study groupRoleWhat they receive
Study dietExperimental4-week therapeutic diet intervention as experimental group
Receives: Other: Dialysis-specific therapeutic diet
Usual dietNo intervention4-week usual diet as control group, no dietary intervention in this group, participants consumed their habitual diet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Concentrations of intact fibroblast growth factor 23 (pg/mL)

    Difference in change-from-baseline intact fibroblast growth factor 23 (pg/mL) between therapeutic diet and usual diet

    Measured: 4 weeks

Secondary outcomes (21)
  1. Concentrations of C-terminal fibroblast growth factor 23 (RU/mL)

    Difference in change-from-baseline C-terminal fibroblast growth factor 23 (RU/mL) between therapeutic diet and usual diet

    Measured: 4 weeks

  2. Concentrations of phosphate (mg/dL)

    Difference in change-from-baseline phosphate (mg/dL) between therapeutic diet and usual diet

    Measured: 4 weeks

  3. Concentrations of calcium (mg/dL)

    Difference in change-from-baseline calcium (mg/dL) between therapeutic diet and usual diet

    Measured: 4 weeks

  4. Concentrations of intact parathyroid hormone (pg/mL)

    Difference in change-from-baseline intact parathyroid hormone (pg/mL) between therapeutic diet and usual diet

    Measured: 4 weeks

  5. Concentrations of bone-specific alkaline phosphatase (μg/L)

    Difference in change-from-baseline bone-specific alkaline phosphatase (μg/L) between therapeutic diet and usual diet

    Measured: 4 weeks

  6. Concentrations of procollagen-type 1 N-terminal-propeptide (P1NP) (ng/mL)

    Difference in change-from-baseline procollagen-type 1 N-terminal-propeptide (P1NP) (ng/mL) between therapeutic diet and usual diet

    Measured: 4 weeks

  7. Concentrations of tartrate resistance acid phosphatase-5b (TRACP-5b) (mIU/ml)

    Difference in change-from-baseline tartrate resistance acid phosphatase-5b (TRACP-5b) (mIU/ml) between therapeutic diet and usual diet

    Measured: 4 weeks

  8. Concentrations of alkaline phosphatase (ALP) (IU/L)

    Difference in change-from-baseline alkaline phosphatase (ALP) (IU/L) between therapeutic diet and usual diet

    Measured: 4 weeks

  9. Concentrations of free indoxyl sulfate (mg/L)

    Difference in change-from-baseline free indoxyl sulfate (mg/L) between therapeutic diet and usual diet

    Measured: 4 weeks

  10. Concentrations of free p-cresol sulfate (mg/L)

    Difference in change-from-baseline free p-cresol sulfate (mg/L) between therapeutic diet and usual diet

    Measured: 4 weeks

  11. Concentrations of pre-albumin (g/dL)

    Difference in change-from-baseline pre-albumin (g/dL) between therapeutic diet and usual diet

    Measured: 4 weeks

  12. Concentrations of albumin (g/dL)

    Difference in change-from-baseline albumin (g/dL) between therapeutic diet and usual diet

    Measured: 4 weeks

  13. Concentrations of C-reactive protein (mg/dL)

    Difference in change-from-baseline C-reactive protein (mg/dL) between therapeutic diet and usual diet

    Measured: 4 weeks

  14. Concentrations of quinolinate

    Difference in change-from-baseline quinolinate between therapeutic diet and usual diet

    Measured: 4 weeks

  15. Concentrations of mesaconate

    Difference in change-from-baseline mesaconate between therapeutic diet and usual diet

    Measured: 4 weeks

  16. Absolute number (per μl blood) of CD4+ (cluster of differentiation 4) T cells

    Difference in change-from-baseline absolute number (per μl blood) of CD4+ (cluster of differentiation 4) T cells between therapeutic diet and usual diet

    Measured: 4 weeks

  17. Absolute number (per μl blood) of CD8+ (cluster of differentiation 8) T cells

    Difference in change-from-baseline absolute number (per μl blood) of CD8+ (cluster of differentiation 8) T cells between therapeutic diet and usual diet

    Measured: 4 weeks

  18. Absolute number (per μl blood) of monocytes

    Difference in change-from-baseline absolute number (per μl blood) of monocytes between therapeutic diet and usual diet

    Measured: 4 weeks

  19. Concentrations of fetuin-A (μg/ml)

    Difference in change-from-baseline fetuin-A (μg/ml) between therapeutic diet and usual diet

    Measured: 4 weeks

  20. Concentrations of trimethylamine-N-oxide (TMAO) (μM)

    Difference in change-from-baseline trimethylamine-N-oxide (TMAO) (μM) between therapeutic diet and usual diet

    Measured: 4 weeks

  21. Difference in change-from-baseline phosphate-binding equivalent dose (PBED) between therapeutic diet and usual diet

    The phosphate-binder doses among the study participants will be compared by calculating the phosphate-binding equivalent dose (PBED) values as described by Daugirdas.

    Measured: 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Apr 2024
  2. Study start1 May 2025
  3. Primary completion4 Dec 2025
  4. Study completionJun 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
A randomized, active-controlled trial with cross-over design
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06377293
Sponsor's protocol ID
FEMH-IRB-TSAI2024
Status last verified
Aug 2025
First submitted
15 Apr 2024
Last updated
31 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual-level deidentified participant data will be made available by the corresponding author of the paper upon request by email. The data will be available for 3 years after formal publication.

Publications

  • Tsai WC, Wu HY, Peng YS, Hsu SP, Chiu YL, Chen HY, Yang JY, Ko MJ, Pai MF, Tu YK, Hung KY, Chien KL. Effects of lower versus higher phosphate diets on fibroblast growth factor-23 levels in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018 Nov 1;33(11):1977-1983. doi: 10.1093/ndt/gfy005.

    PubMed 29420827
  • Tsai WC, Peng YS, Wu HY, Hsu SP, Chiu YL, Liu LC, Tsai SM, Chien KL. Accuracy of a Nutrient Database in Estimating the Dietary Phosphorus-to-Protein Ratio and Using a Boiling Method in Low-Phosphate Hospital Diets. Sci Rep. 2018 Oct 15;8(1):15246. doi: 10.1038/s41598-018-33657-8.

    PubMed 30323203
  • Tsai WC, Wu HY, Peng YS, Hsu SP, Chiu YL, Yang JY, Chen HY, Pai MF, Lin WY, Hung KY, Chu FY, Tsai SM, Chien KL. Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial. Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1475-1483. doi: 10.2215/CJN.04250419. Epub 2019 Sep 13.

    PubMed 31519550
  • Tsai WC, Wu HY, Chiu YL, Yang JY, Pai MF, Wu YR, Lin WY, Hung KY, Chien KL, Hsu SP, Peng YS. Acute effects of dietary phosphorus intake on markers of mineral metabolism in hemodialysis patients: post hoc analysis of a randomized crossover trial. Ren Fail. 2021 Dec;43(1):141-148. doi: 10.1080/0886022X.2020.1870138.

    PubMed 33427559
  • Tsai WC, Hsu SP, Chiu YL, Wu HY, Luan CC, Yang JY, Pai MF, Lin CJ, Lin WY, Sun WH, Peng YS. Short-Term Effects of a Therapeutic Diet on Biochemical Parameters in Hemodialysis Patients: A Randomized Crossover Trial. J Ren Nutr. 2023 Nov;33(6):731-739. doi: 10.1053/j.jrn.2023.04.003. Epub 2023 Apr 27.

    PubMed 37120127

Questions about this trial

What is this clinical trial studying?

A study testing Dialysis-specific therapeutic diet in people with End-Stage Kidney Disease, run by Far Eastern Memorial Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Concentrations of intact fibroblast growth factor 23 (pg/mL) (time frame: 4 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06377293, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in